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A B S T R A C T
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have
clearly demonstrated their beneficial effect in diabetic kidney
disease (DKD) on top of the standard of care [blood glucose
control, renin–angiotensin system blockade, smoking cessation
and blood pressure (BP) control], even in patients with overt
DKD. However, the indication of this drug class is still blood
glucose lowering in type 2 diabetic patients with estimated glo-
merular filtration rate >45 mL/min/1.73 m2. Based on the new
evidence, several scientific societies have emphasized the prefer-
ential prescription of SGLT2i for patients at risk of heart failure
or kidney disease, but still within the limits set by health author-
ities. A rapid positioning of both the European Medicines
Agency and the US Food and Drug Administration will allow
patients with overt DKD to benefit from SGLT2i. Clinical expe-
rience suggests that SGLT2i safety management may in part
mirror renin–angiotensin blockade safety management in
patients with overt DKD. This review focuses on the rationale
for an indication of SGTL2i in DKD. We further propose clini-
cal steps for maximizing the safety of SGLT2i in DKD patients
on other antidiabetic, BP or diuretic medication.
Keywords: chronic renal failure, diabetic kidney disease,
ESRD, SGLT2 inhibitors, type 2 diabetes
I N T R O D U C T I O N
Diabetic kidney disease (DKD) is the most frequent cause of
end-stage kidney disease (ESKD) in developed countries [1–3].
Until 2016, the mainstay of DKD treatment was renin–angio-
tensin system (RAS) blockade [4]. From 2016, sodium-glucose
cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated
beneficial effects in DKD on top of the standard of care, namely
blood glucose control, RAS blockade, smoking cessation and
blood pressure (BP) control [5–9]. Initially, SGLT2i was devel-
oped to lower plasma glucose in type 2 diabetes mellitus
(T2DM) patients, but large randomized controlled trials
(RCTs) have demonstrated both renal and cardiovascular pro-
tection in T2DM beyond the benefits derived from improved
glycaemic control.
The renoprotective effects of SGLT2i were first observed in
three large trials evaluating cardiovascular safety:
Empagliflozinn, cardiovascular, Cardiovascular Outcomes, and
Mortality in Type 2 Diabetes (EMPA-REG OUTCOME),
Canagliflozin and Cardiovascular and Renal Events in Type 2
Diabetes (CANVAS Programme), and Dapagliflozin and
Cardiovascular Outcomes in Type 2 Diabetes (DECLARE-
TIMI 58). In these studies, SGLT2i reduced albuminuria pro-
gression, prevented glomerular filtration rate (GFR) decline and
decreased the incidence of renal replacement therapy in T2DM
patients without overt DKD [5, 6, 8]. Three further trials ad-
dress the kidney effects of SGLT2i on patients with overt DKD:
Canagliflozin and Renal Outcomes in Type 2 Diabetes and
Nephropathy (CREDENCE), Dapagliflozin on Renal Outcomes
and Cardiovascular Mortality in Patients with Chronic Kidney
Disease (DAPA-CKD), and the Study of Heart and Kidney
Protection With Empagliflozin (EMPA-KIDNEY). In April
2019, the CREDENCE trial’s striking results on kidney and
VC The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial














ent_1/i13/5718402 by guest on 16 N
ovem
ber 2020
heart protection were published [7]. In concordance with
DAPA-CKD results, some authors suggest the potential use of
SGLT2i on top of RAS blockade in the early stages of DKD,
when T2DM patients mainly exhibit hyperfiltration and mild
albuminuria. With this approach, one expects that the cardiore-
nal protective effect of this treatment will be offered as preven-
tion and not delayed to the already established DKD [10].
However, further studies in pre-diabetic patients are needed to
confirm this hypothesis.
There were initial safety concerns as SGLT2i adverse drug
reactions (ADRs) included acute kidney injury (AKI), diabetic
ketoacidosis (DKA), amputations, urinary and genital tract
infections (UTIs), bladder cancer and bone fractures [11].
However, recent trials have downplayed these risks and the
benefit/risk balance remains positive. Interestingly, in a pooled
analysis of 11 Phase 3 RCTs, dapagliflozin use in patients with
estimated GFR (eGFR) between 12 and 45 mL/min/1.73 m2
(CKD G3b–4) decreased the urinary albumin creatinine ratio
(UACR), BP and body weight without modulating glycated he-
moglobin (HbA1c) or increasing major side effects [10]. This
observation supports the concept of positive renal and cardiac
effects of SGLT2i independent from glycaemic control.
In this review, we describe the molecular mechanism in-
volved in cardiorenal protection in DKD and the current indi-
cations for SGLT2i treatment in DKD patients according to the
European Medicines Agency (EMA) and the US Food and
Drug Administration (FDA), as well as suggestions by the sci-
entific community to update the indication to include overt
DKD. We also propose clinical practice recommendations for
the safe use of SGLT2i in DKD patients on other antidiabetic,
hypertension and diuretic treatments.
N E W M O L E C U L A R M E C H A N I S M S I N
C A R D I O R E N A L P R O T E C T I O N W I T H S G L T 2
I N H I B I T I O N
SGLT2i have become a promising option to treat T2DM as they
decrease glycaemia and improve insulin resistance without pro-
ducing severe hypoglycaemia [12]. In a meta-analysis published
by Yang et al. [13], SGLT2i was demonstrated to reduce HbA1c
and insulin dosage both in types 1 and 2 diabetic patients. This
decrease in insulin doses could reflect an improvement in insulin
resistance, which is a key mediator of type 2 diabetes [14].
Furthermore, it might in part explain the weight loss induced by
this drug class. SGLT2i additionally reduces cardiovascular com-
plications and slows DKD progression [5, 6, 8, 15–17]. Diverse
experimental and clinical studies suggest that the cardiorenal
protection exerted by SGLT2i may be explained by mechanisms
independent of glycaemia and BP control.
SGLT2 is a glucose/sodium (Naþ) cotransporter located at
the apical membrane of proximal tubular cells that drives glu-
cose into cells together with Naþ. It is responsible for the reab-
sorption of 90% of the filtered glucose load [18–20]. In diabetic
patients, the increase in filtered glucose enhances SGLT2 activ-
ity, which worsens glycaemic control and promotes Naþ load-
ing, impairing BP control [21]. Moreover, proximal tubular
Naþ reabsorption results in decreased Naþ availability at distal
tubules and reduces macula densa adenosine signalling to
afferent arterioles. The signalling reduction leads to afferent ar-
teriole vasodilation, increases intraglomerular pressure and
causes hyperfiltration. Naþ/Hþ exchanger isoform 3 (NHE3) is
a proximal tubule Naþ transporter closely regulated by glucose
metabolism and SGLT transporters, which makes it sensitive to
SGLT2i [22]. In Otsuka Long-Evans Tokushima Fatty diabetic
rats, empagliflozin decreased the tubular expression of NHE3,
the Naþ–Kþ–2Cl cotransporter and the epithelial Naþ chan-
nel as compared with untreated littermates [23]. Therefore,
SGLT2i lowers glycaemia and additionally promotes natriuresis
by inhibiting both SGLT2 activity and other Naþ transporters
such as NHE3. Thus, the natriuretic effect may contribute to
cardiorenal benefits by lowering arterial pressure and re-
activating renal tubulo-glomerular feedback signalling from the
macula densa that decreases intraglomerular pressure and
hyperfiltration. However, prior to SGLT2i use, no other diuretic
demonstrated clear cardiorenal protective effects in diabetic
patients although they reduced BP or volume overload. For this
reason, we believe that the beneficial effects exerted by SGLT2i
are the conjunction of diverse molecular mechanisms acting to-
gether. More studies on the bench side are needed to elucidate
the involved pathways.
Beyond the antidiabetic and natriuretic properties, studies in
non-diabetic mice and rats suggest that SGLT2i may exert addi-
tional direct kidney- or heart-protective actions [24–28].
Although in some settings SGLT2i did not prevent kidney dam-
age, in most non-diabetic CKD models, they did decrease kidney
fibrosis and inflammation [24–28]. The discrepant results may
depend on the nature of the different insults tested: SGLT2i did
not protect from chronic oxalosis [24] or subtotal nephrectomy
[25], while it protected from unilateral ureteral obstruction [26],
ischaemia–reperfusion [27] and protein overload [28]. In cul-
tured human tubular cells (HK-2), transforming growth factor
beta 1 (TGF-b1) upregulated SGLT2 and type IV collagen expres-
sion, and this was prevented by empagliflozin through nuclear
factor-jB/Toll-like receptor 4 (NF-jB/TLR4) pathway inhibition,
thus linking a key mechanism of DKD and non-DKD CKD pro-
gression to SGLT2 [29]. Furthermore, both mice and human glo-
merular cells also express SGLT2. Indeed, albumin upregulated
SGLT2 in mice with protein-overload proteinuria, in albuminuric
CKD patients and in cultured human podocytes [28]. Overall, the
available evidence of benefit in non-diabetic models supports the
existence of glucose-independent nephroprotective effects, and
this hypothesis will be addressed in RCTs [26–30].
In search of further molecular targets and downstream
mediators of SGLT2i effects, the canagliflozin mechanism of
action (MoA) network was explored combining cultured tubu-
lar cell transcriptomics profiles and protein expression data
from the scientific literature. This identified 44 proteins related
to the canagliflozin MoA molecular model that overlapped
with proteins in the DKD network model, and 10 of them were
involved in DKD progression [31]. Assessment of these in
plasma from diabetic patients with UACR> 1.7 mg/mmol in-
cluded in the efficacy and safety of canagliflozin versus glime-
piride in patients with type 2 diabetes inadequately controlled
with metformin (CANTATA-SU trial) identified four candi-
date factors [tumour necrosis factor receptor 1 (TNFR1),
interleukin (IL)-6, matrix metalloproteinase 7 (MMP-7) and
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fibronectin 1 (FN1)] that were decreased by canagliflozin, sup-
porting the concept that SGLT2i may modulate inflammatory
and fibrosis processes in DKD [31, 32]. In addition, the effects
of two SGLT2i (empagliflozin and canagliflozin) and TGF-b1
on gene expression in two human proximal tubular cell lines
were studied [33]. All 94 genes, mainly related to extracellular
matrix organization, which were upregulated by TGF-b1 and
downregulated by the two SGLT2i were identified. Three of
these genes [thrombospondin 1 (THBS1), tenascin C (TNC)
and platelet-derived growth factor subunit B (PDGF-B)] re-
lated to renal fibrosis and CKD progression were then validated
on mRNA expression in both cell lines, proving that SGLT2i is
able to suppress these genes.
Cardioprotection by SGLT2i has been widely attributed to
the improved glycaemia and BP control [34]. However, a direct
effect on the heart cannot be disregarded since there is an ongo-
ing controversy on whether SGLT2 is expressed in the heart [35–
39]. Recent data support direct effects on the heart since empa-
gliflozin improved high glucose-induced cardiomyocyte dys-
function [40]. Empagliflozin also ameliorated cardiac function
in pressure overload-induced heart failure in mice [41] and
delayed ischaemic contracture in isolated mouse hearts in an
insulin-dependent manner [42]. This last effect may depend
on direct inhibition of the Naþ/Hþ transporter NHE1 as
empagliflozin interacts with its Naþ-binding domain [42, 43].
NHE1 and NHE3 belong to the same family of Naþ/Hþ trans-
porters. NHE1 is virtually ubiquitously expressed and is re-
sponsible for intracellular pH maintenance, while NHE3
expression is restricted to epithelial tissues where it also con-
tributes to transepithelial transport [44]. As mentioned before,
in kidney tubules, NHE3 activity depends on SGLT2-mediated
glucose transport [22]. It may be speculated that a similar
mechanism applies to NHE1 in the heart [22, 40]. Thus, cardi-
oprotection by SGLT2i may also depend on direct inhibition
of local SGLT2. Finally, empagliflozin increased glucose trans-
porter-1 (GLUT-1) mediated glucose transport in isolated car-
diomyocytes [45], and this could also contribute to SGLT2i
cardioprotection.
In summary, there is evidence that SGLT2i exert pleiotropic
tissue-protective effects via different mechanisms (Supplementary
data, Figure S1): (i) reduction of glycaemia, BP and volume over-
load; (ii) SGLT2 inhibition in kidney tubules leading to improved
metabolic control, natriuresis and decreased hyperfiltration; (iii)
local SGLT2 inhibition in other organs, such as the heart [40, 41]
or the pancreas [46]; and (iv) SGLT2-independent interference
with Naþ/Hþ transporters.
W H E N T O S T A R T S G L T 2 I N D I A B E T I C
P A T I E N T S ?
As of June 2019, regulatory and scientific society statements
and recommendations on the indications and timing of SGLT2i
prescriptions differ. This likely reflects the different processing
timelines for the wealth of recent information from high cardio-
vascular risk and DKD RCTs (Table 1) [5–8, 15]. The EMA cur-
rent indication for SGLT2i is the treatment of insufficiently
controlled T2DM as an adjunct to diet and exercise, either as
monotherapy when metformin is considered inappropriate due
to intolerance or in addition to other medicinal products for the
treatment of diabetes, although dapagliflozin may also be used
in T1DM (Table 2) [47–51]. Recently, the EMA recognized the
positive effect of dapagliflozin on cardiovascular events.
However, the US FDA was the first to acknowledge the specific
indications in T2DM patients with cardiovascular disease
(CVD) to reduce major adverse cardiovascular events (MACEs)
for canagliflozin and to reduce cardiovascular death for empa-
gliflozin, based on RCT results (Tables 1 and 2) [47–51]. While
the US FDA specifically warns against the use of any SGLT2i in
T1DM, the EMA admits the use of dapagliflozin for this indica-
tion. Overall, the FDA appears to have moved faster than the
EMA in response to cardiovascular safety trial results and
clearly distinguishes between specific indications for each drug
as per RCT results (Figure 1A). The rapid response is likely re-
lated to the FDA request for these trials, and an indication for
the treatment of DKD is undergoing priority review. In con-
trast, the EMA does not state large differences between the three
drugs either in indication or in the use according to eGFR data.
There are additional differences between major regulatory
agencies regarding SGLT2i contraindications for DKD patients
with decreased eGFR (Table 3 and Figure 1B).
Since 2016, scientific societies have also suggested the role of
SGLT2i in patients with T2DM and specific comorbidities.
Table 2 summarizes some of the key position manuscripts.
Overall, scientific societies recommend considering SGLT2is as
preferential agents to treat T2DM on top of metformin when
patients have atherosclerotic CVD, heart failure or DKD.
Contrary to the FDA, which provides different regulatory ad-
vice for each drug according to specific cardiovascular safety
trial results, scientific societies usually use the generic term
‘SGLT2i’ or ‘SGLT2i with evidence of cardiovascular or renal
protection’. Additionally, given the striking benefit over heart
failure hospitalization, the preferential use of SGLT2i for
patients with heart failure is suggested or recommended, al-
though this was not a primary outcome of cardiovascular safety
trials. Scientific societies fall short of recommending the use of
SGLT2i outside the eGFR limits provided by regulatory author-
ities (Table 3). It is likely that the range of eGFR at which cana-
gliflozin can be prescribed will expand in the near future, given
the renal benefit observed in the CREDENCE trial of canagliflo-
zin versus placebo in patients with overt DKD, in which
patients were enrolled with eGFR30 mL/min/1.73 m2, and
canagliflozin was not stopped until renal replacement therapy
was initiated (Supplementary data, Figure S2A). We believe
that this supports an indication of canagliflozin at any eGFR
value in non-dialysis patients, always with the caveat that initia-
tion of SGLT2i may decrease the baseline eGFR as it decreases
hyperfiltration. In this regard, in T2DM patients with DKD,
canagliflozin decreased the relative risk of a composite primary
outcome of ESKD (dialysis, transplantation or a sustained esti-
mated GFR of< 15 mL/min/1.73 m2), doubling of the serum
creatinine level or death from renal or cardiovascular causes by
30% versus placebo [hazard ratio (HR) ¼ 0.70; 95% confidence
interval (CI) 0.59–0.82; P¼ 0.00001] [7]. More specifically, a
hard component of the composite, the residual risk of ESKD was
reduced to 2/100 patient-years of follow-up (Supplementary
data, Figure S2B). Taken together with beneficial effects over
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pre-specified renal outcomes such as incident or worsening
nephropathy (progression to macroalbuminuria, doubling of se-
rum creatinine, initiation of renal replacement therapy or death
from renal disease) and incident albuminuria in patients with
milder or no evidence of DKD in cardiovascular safety trials [5,
17], overall data point to a nephroprotective effect at different
stages of DKD that warrants preferential use of SGLT2i to treat
T2DM patients from very early in the course of DKD, and even
before its occurrence to prevent or delay it. The kidney outcomes
success of SGLT2i trials for T2DM has set the stage for addi-
tional trials enrolling non-T2DM patients [30].
S G L T 2 A N D D K D : P R O S A N D C O N S
Three large cardiovascular safety trials—EMPA-REG
OUTCOME, the CANVAS programme and DECLARE-TIMI
58—demonstrated that SGLT2i reduced albuminuria progres-
sion, prevented GFR decline and decreased the incidence of
renal replacement therapy [5, 8, 11, 15, 17, 52]. However, these
were secondary endpoints and few patients had moderate-to-
severe DKD (Table 1), so information on patients with A3 albu-
minuria or GFR<60 mL/min/1.73 m2 was limited. Two ongoing
(DAPA-CKD and EMPA-KIDNEY) and one just completed
(CREDENCE) RCTs test with different SGLT2i for primary renal
endpoints in patients with overt DKD. The CREDENCE trial
evaluated the impact of SGLT2 inhibition (canagliflozin 100 mg
daily) against placebo in patients with T2DM and DKD defined
as UACR>300 mg/g with eGFR from 30 to 90 mL/min/1.73 m2
[1, 7]. CREDENCE was stopped prematurely because the pre-
specified efficacy criteria for early cessation were reached, thus
providing evidence of renal and heart protection in a population
partly excluded from prior RCTs [53]. Regarding safety, rates of
adverse events were similar between groups, with the exception
of DKA (2.2 versus 0.2 events per 1000 patient-years in canagli-
flozin and placebo patients, respectively) and genital mycotic in-
fection—especially, in male patients—which were more frequent
in the canagliflozin group.
Despite the increasing evidence of SGLT2i efficacy in DKD,
the use of this drug class is still limited to patients with eGFR
>45 mL/min/1.73 m2. This restriction may be ascribed to two
main reasons: (i) SGLT2i were designed as antidiabetic drugs
and their antidiabetic effects depend on the magnitude of gly-
cosuria, which is limited in patients with decreased GFR [54];
and (ii) given the mechanism of action, there was no rationale
for their use as antidiabetic agents in patients with an
eGFR<45 mL/min/1.73 m2. Accordingly, they were not even
tested in large numbers of patients with low eGFR, until now.
Although exploratory trials had evaluated the efficacy and
safety of SGLT2i in established DKD [54], their clinical impact
was low, as the sample size was small, the duration short and re-
nal outcomes were not assessed. Interestingly, a meta-analysis
of 4000 patients with eGFR from 45 to 60 mL/min/1.73 m2
from 11 RCTs demonstrated consistent positive effects of dapa-
gliflozin on BP, body weight, haematocrit, albuminuria, eGFR,
bicarbonate, pulse pressure and uric acid. CREDENCE con-
firmed kidney and cardiovascular benefits for patients starting
canagliflozin in overt DKD patients (G3a and G3b,
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start of dialysis [7]. This evidence should be sufficient for the
approval of the use of this drug class or at least of canagliflozin
in patients with eGFR<45 mL/min/1.73 m2.
The overall safety record of SGLT2i in patients with
moderate-to-severe DKD has been positive [17, 54]. Adverse
events were more frequent in patients receiving higher doses of
this drug class. However, in CREDENCE, a low canagliflozin
dose of 100 mg/day was nephroprotective and safe, suggesting
that lower SGLT2i doses achieved renal and heart protection in
patients with overt DKD, with eGFR<45 mL/min/1.73 m2
(mean eGFR 56 mL/min/1.73 m2) [7].
S A F E T Y O F S G L T 2 i : I S T H E R E A C L A S S
E F F E C T ?
Potential ADRs of SGLT2i include AKI [55], DKA [56], foot
and toe amputations [17], UTI and genital infections [57],
bladder cancer [58] and bone fractures [59]. The most consis-
tent associations have been with DKA, UTI and genital infec-
tions. From 2015 to 2018, the FDA has issued six warnings
about ADRs linked to SGLT2i. A review on the safety profile of
SGLT2i that selected 27 studies for risk analysis concluded that
causality assessment disclosed a correlation between SGLT2i
and DKA and UTI [60]. A systematic review and meta-analysis
of RCT that included SGLT2i up to May 2018 [61] selected 109
reports on SGLT2i, mainly dapagliflozin, canagliflozin, empa-
gliflozin and ipragliflozin. When compared with placebo,
SGLT2i decreased the risk of AKI (RR¼ 0.59; 95% CI 0.39–
0.89; I2¼ 0.0%), while no difference was found for DKA (RR ¼
0.66; 95% CI 0.30–1.45, I2¼ 0.0%), UTI (RR ¼ 1.02; 95% CI
0.95–1.09, I2¼ 0.0%) or bone fracture (RR ¼ 0.87; 95% CI
0.69–1.09, I2¼ 1.3%). Three studies reported on amputation,
with one finding a significantly increased risk. Subgroup analy-
sis did show an increased risk of UTI with dapagliflozin only
(RR¼ 1.21; 95% CI 1.02–1.43, I2¼ 0.0%), but no other analysis
supported an increased risk of AKI, DKA, UTI or fracture. The
authors concluded that evidence from RCTs did not suggest an
increased risk of harm with SGLT2i as a class over placebo or
active comparators with respect to AKI, DKA, UTI or fracture.
However, wide CIs for many comparisons suggest limited pre-
cision, and, therefore, clinically important ADRs could not be
ruled out.
In the CANVAS programme, 10 142 T2DM patients were
randomly allocated to canagliflozin 100 or 300 mg/day or pla-
cebo [18]. Canagliflozin was associated with a significant dou-
bling in the risk for amputations, mainly toe and metatarsal
amputations (6.3 versus 3.4 cases per 1000 patient-years, HR¼
1.97, 95% CI 1.41–2.75) [62]. The risk was similar for ischaemic
and infective aetiologies and for 100 and 300 mg doses. Overall
amputation risk was strongly associated with baseline history of
prior amputation (major or minor) (HR ¼ 21.31, 95% CI
15.40–29.49) and other established risk factors. No interactions
between randomized treatment and participant characteristics
explained the effect of canagliflozin on amputation risk. For ev-
ery clinical subgroup studied, numbers of amputation events
projected were smaller than the numbers of MACE averted
(HR ¼ 1.97). Additionally, no differences in the incidence
of amputations were observed in the CREDENCE RCT in
patients with DKD randomized to 100 mg/day canagliflozin.
Interestingly, when CREDENCE was started the amputations
warning regarding the CANVAS study was already released,
and investigators were aware of this ADR. However, no differ-
ences regarding baseline peripheral artery disease between the
two studies were observed. In the DECLARE study, comparing
dapagliflozin versus placebo added to standard care in 17 160
patients followed for a median of 4.2 years, there were no differ-
ences in the incidence of amputations, stroke or fractures, with
a significant increase of UTI or genital infections and DKA.
Moreover, there was a lower risk of hypoglycaemia, AKI and
bladder cancer in the dapagliflozin-treated group (Supplementary
data, Tables S1 and S2) [8]. To clarify whether the amputation
risk could be a class effect of SGLT2i, a thorough collection of pro-
spective data on amputations and other foot-related complica-
tions is required in all ongoing and future long-term randomized
clinical trials (e.g. DAPA-CKD, Dapagliflozin in Patients with
Regulatory status of SGLT2i as of June 2019
Canagliflozin Dapagliflozin Empagliflozin





























FIGURE 1: (A) Regulatory status regarding indications of SGLT2i as
of June 2019. The FDA differentiates between the indications of the
three SGLT2i according to T2DM patient characteristics, while the
EMA does not. In contrast, EMA allows the use of dapagliflozin in
T1DM, while the FDA warns against the use of any of these drugs in
T1DM. (B) Regulatory status regarding use in individuals with de-
creased eGFR of SGLT2i as of June 2019. Language such as ‘contra-
indicated’ or ‘should not be used’ has been considered equivalent.
Discontinuous line represents the situation in which the drug was
initiated prior to the deterioration of renal function. Based on the
results of the CREDENCE trial [7], we anticipate that at least for
canagliflozin, usage will be allowed in the near future up to the initia-
tion of renal replacement therapy.
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Heart Failure and Reduced Ejection Fraction (DAPA-HF) and
DECLARE with dapagliflozin; EMPagliflozin outcomE tRial in
Patients With chrOnic heaRt Failure With Preserved Ejection
Fraction (EMPEROR-Preserved) and EMPagliflozin outcomE
tRial in Patients With chrOnic heaRt Failure With Reduced
Ejection Fraction (EMPEROR-Reduced); and Cardiovascular
Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes
Mellitus Participants With Vascular Disease (VERTIS CV) with
ertugliflozin).
Recently, the use of SGLT2i has been also associated with
Fournier gangrene, a rare urologic emergency characterized
by necrotizing infection of the external genitalia, perineum
and perianal region. The FDA identified 55 unique cases of
Fournier gangrene in patients receiving SGLT2i between 1
March 2013 and 31 January 2019. Age ranged from 33 to
87 years; 39 were men and 16 were women. Time to onset af-
ter SGLT2i initiation ranged from 5 days to 49 months. All
patients had DKA (n¼ 8), sepsis or septic shock (n¼ 9) and
AKI (n¼ 4). Eight patients had faecal diversion surgery, two
developed necrotizing fascitis of a lower extremity that re-
quired amputation and one required a lower extremity by-
pass procedure because of gangrenous toes. Three patients
died. For comparison, the FDA identified 19 Fournier gan-
grene cases associated with other antidiabetic agents be-
tween 1984 and 31 January 2019: metformin (n¼ 8), insulin
glargine (n¼ 6), short-acting insulin (n¼ 2), sitagliptin plus
metformin (n¼ 2), and dulaglutide (n¼ 1). These patients
ranged in age from 42 to 79 years; 12 were men and 7 were
women. Two patients died [63]. These findings merit further
research.
In conclusion, genital infections are probably the most fre-
quent and documented ADR of the SGLT2i. Other potential
ADRs are less consistent and variable data can be found in differ-
ent RCTs and meta-analysis. Given the similar molecular struc-
ture of the available SGLT2i, it is plausible that ADRs observed
until now are a class effect. The discrepancies observed in the
published RCTs may be ascribed to the differences in patient
characteristics as well as in evolving clinical experience with these
agents rather than to differences between specific SGLT2i.
C L I N I C A L R E C O M M E N D A T I O N S F O R T H E
U S E O F S G L T 2 I N H I B I T O R S I N D K D
A multifactorial intervention is still the best therapeutic ap-
proach to T2DM with or without DKD. These include imple-
menting lifestyle interventions, promoting weight loss
(healthy diet and exercise) in obese patients, reducing low-
density lipoprotein cholesterol levels using statins, treating
BP preferentially with RAS blockade and improving glycae-
mic control [51, 64]. For the latter objective, metformin is
still considered the first pharmacological option if tolerated,
although safety and prescribed doses should be revised if
eGFR is 30–60 mL/min/1.73 m2 and the fact sheet recom-
mends stopping the drug when eGFR falls below 30 mL/min/
1.73 m2 [65], although this is a debated issue. Recent consen-
sus documents have addressed the place of SGLT2i and glu-
cagon-like peptide-1 receptor agonists (GLP-1RAs), in light
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These documents consider SGLT2i and GLP-1RAs as sec-
ond-line therapy in both DKD with unmet glycaemic control
(HbA1c>7%) and for controlled DKD patients (HbA1c<7%).
Specifically, consensus documents recommend the use of
SGLT2i in T2DM patients with established CVD or DKD. These
changes shift the focus of this drug prescription from glycaemic
control to improved kidney and cardiovascular outcomes.
The mechanistic effect of this drug class, including natriure-
sis and glycosuria, guides the concomitant use of other drugs
and suggests some preventive measures to increase safety when
initiating SGLT2i treatment in patients with CKD on other
antidiabetic drugs or diuretics. Thus, the lower antidiabetic effi-
cacy of SGLT2i at low eGFR may require a combination with
other antidiabetic agents [67]. Severe hypoglycaemia is rarely
described with the use of SGLT2i and is usually associated with
the add-on therapy to other hypoglycaemic drugs [54, 67].
To prevent hypoglycaemic events in DKD patients, other anti-
diabetic drugs should be titrated, reduced or withdrawn before
starting SGLT2i (Figure 2). This recommendation is particularly
important in DKD patients on sulphonylureas (SU) and/or on
insulin, which is already associated with an increased risk of
hypoglycaemia in CKD [54, 67]. Combination with other anti-
diabetic drugs, such as GLP-1RAs or metformin, has a much
lower risk of hypoglycaemic events [69]. Because of the diuretic
effect, doses of other diuretic medications should also be revised
and in many cases decreased when starting SGLT2i in DKD
patients (Figure 2). In elderly or frail patients, who may have a
lower water intake or access, SGLT2i therapy should be carefully
initiated and closely monitored.
The routine risk management strategy for SGLT2i is very
similar to that for RAS blockers, which is familiar for both
patients and physicians. Thus, patients on SGLT2i treatment
should be advised to temporarily discontinue the drug if acutely
ill, especially in the presence of vomiting, diarrhoea or de-
creased water intake, to avoid dehydration and volume deple-
tion. Similarly, SGLT2i should be transiently withdrawn during
acute infections, fever, surgery and other insulin counter-
regulatory states to prevent DKA [67, 70]. DKA is a rare but se-
vere complication of SGLT2i treatment that, unlike classic
DKA, is usually associated with mild-to-moderate serum
Recommendations for SGLT2 inhibitors use
Other antidiabetic drug or insulin treatment?
Insulin+ or SU++
→ Consider reducing dose if HbA1c <8.5%  
or documented hypoglycemic events.
Other antidiabetic drugs
-metformin, GLP-1 RAs, DPP-4i or glinides-
→ Dose adjustment not usually required.
Diuretic treatment?
→ Consider reducing dose in elderly 




→ Consider reducing dose in elderly patients, BP <140/80 
mmHg or documented hypotensive symptoms. 
→ Prescribe SGLT2 inhibitor, informing the patient 
about possible adverse events and recommendations.
NoYes
FIGURE 2: Recommendations before starting treatment with SGLT2i. þA decrease of 20% of the insulin dose is recommended, especially if
there are previously reported hypoglycaemic events or the eGFR is <60 mL/min/1.73 m2. þþSulphonylureas (SU) should be withdrawn if
eGFR falls below 45 mL/min/1.73 m2. DPP-4i, dipeptidyl peptidase 4 inhibitor GLP-1 RAs, glucagon-like peptide-1 receptor agonists. Adapted
from reference [68].
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glucose elevations. DKA may be precipitated by fasting, alcohol
intake, excessive reduction of insulin doses, dehydration or
acute processes, although some cases remain unexplained [71].
To avoid DKA, SGLT2i should be initiated at the lowest dose
possible when blood ketone levels are <0.6 mmol/L [72].
Moreover, it is not advisable to start this drug class in patients
with an already known low reservoir of endogenous insulin or
low C-peptide. It is recommended that patients self-monitor
capillary blood ketones when DKA is suspected, but urine
ketones monitoring would be enough. SGLT2i therapy should
be discontinued if ketone levels increase. Proper education is
important for both the patient and the clinician to be fully
aware of factors impacting ketone levels and the protocol to fol-
low if ketone levels increase. In concordance, a nephrologist
should suspect euglycaemic DKA when called as consultant in
the emergency department for a severe metabolic acidosis with
high anion gap in a diabetic patient under SGLT2i therapy.
SGLT2i may be not initiated if hypovolaemia or peripheral vas-
cular disease is present or in older frail patients.
C O N C L U S I O N S
In conclusion, emerging evidence derived from RCTs and
meta-analyses point to cardioprotective and nephroprotective
effects of SGLT2i that are maintained in patients with full-
blown DKD with baseline eGFR up to 30 mL/min/1.73 m2. The
use of at least one of these drugs, canagliflozin at the 100 mg/
day dose, was safe and associated with benefits in DKD patients
that maintain the drug up to the start of renal replacement ther-
apy. Scientific societies have moved to recommend the prefer-
ential use of SGLT2i in patients with DKD. It is expected that
regulatory authorities will increase the range of eGFR at which
SGLT2i can be used, as well as modify the indications to include
nephroprotection. In addition, the development of multidisci-
plinary teams, including a nephrologist, cardiologist, endocri-
nologist and primary care doctor for the management of high-
risk type 2 diabetic patients (previous history of CVD or DKD),
would improve the proper implementation of this class of anti-
hyperglycaemic drugs in clinical practice. SGLT2i are generally
safe, and some of the initial safety concerns have not been con-
firmed in more recent RCTs. In any case, both physicians and
patients should be well aware of potential ADRs and instructed
to discontinue the drug in certain circumstances. Given the pro-
tection afforded in patients with low eGFR, where the contribu-
tion of improved metabolic control is minimal, it is thought
that the molecular mechanisms of cardiovascular and kidney
protection expand beyond lowering serum glucose levels. In
this regard, RCTs that explore cardiovascular and kidney pro-
tection even in patients without T2DM are ongoing.
S U P P L E M E N T A R Y D A T A
Supplementary data are available at ndt online.
F U N D I N G
FIS/Fondos FEDER (PI16/02057, PI17/00257, ISCIII-
RETIC REDinREN RD016/0009), FRIAT, Sociedad
Espa~nola de Nefrologı́a, Comunidad de Madrid en
Biomedicina B2017/BMD-3686 CIFRA2-CM, and CIBER
CV 16/11/00420.
C O N F L I C T O F I N T E R E S T S T A T E M E N T
A.O. has received speaker fees from Sanofi-Genzyme, Amgen,
Fresenius Medical Care, Mundipharma, Amicus and Freeline.
M.J.S. has received speaker fees or travel support from
Otsuka, Menarini, Astrazeneca, Boehringer Ingelheim,
Janssen, Mundipharma, Novartis, Eli Lilly, Esteve and
Novonordisk. J.F.N.-G. has served as a consultant, and has re-
ceived speaker fees or travel support from Abbvie, Amgen,
AstraZeneca, Boehringer Ingelheim, Esteve, Genzyme, Lilly,
Novartis, Servier, Shire and Vifor Fresenius Medical Care
Renal Pharma. J.L.G. has received fees for giving talks from:
Astrazeneca, Boehringer Ingelheim, Janssen, Mundipharma,
Novartis, Novonordisk, Otsuka and Vifor Pharma. A.M.C.
has received speaker fees from Boëhringer-Ingelheim, Lilly,
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